ABSTRACT
Objective SARS-CoV-2 has significantly impacted Georgia, USA including two major hotspots, Metro Atlanta and Dougherty County in southwestern Georgia. With government deliberations about relaxing social distancing measures, it is important to understand the trajectory of the epidemic in the state of Georgia.
Methods We collected daily cumulative incidence of confirmed COVID-19 cases in Georgia. We estimated the reproductive number (Re) of the COVID-19 epidemic on April 18 and May 2 by characterizing the initial growth phase of the epidemic using the generalized-growth model.
Results The data presents a sub-exponential growth pattern in the cumulative incidence curves. On April 18, 2020, Re was estimated as 1.20 (95% CI: 1.10, 1.20) for the state of Georgia, 1.10 (95% CI: 1.00, 1.20) for Dougherty County, and 1.20 (95% CI: 1.10, 1.20) for Metro Atlanta. Extending our analysis to May 2, 2020, Re estimates decreased to 1.10 (95% CI: 1.10, 1.10) for the state of Georgia, 1.00 (95% CI: 1.00, 1.10) for Dougherty County, and 1.10 (95% CI: 1.10, 1.10) for Metro Atlanta.
Conclusions Transmission appeared to be decreasing after the implementation of social distancing measures. However, these results should be interpreted with caution when considering relaxing control measures due to low testing rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. ICHF acknowledges salary support from the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (19IPA1908208). This article is not part of ICHF’s CDC-sponsored projects.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the analysis is presented in the Supplementary Materials.